fatty liver disease News
-
Independent Clinical Study Shows Seravue® Has High Sensitivity And Specificity For The Detection Of Liver Cancer In Nafld And Related Cirrhotic Patients
A recent study has been published by investigators at the University of Turin in the peer-reviewed journal Current Oncology. This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the ...
-
New Approaches to the Old Hunt for NASH Therapies
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH is characterized by the presence of an abnormal accumulation of fat in the liver. As ...
-
Sonic Incytes Showcases Velacur at ACG 2021
Breakthrough imaging solution for liver health offers physicians an accurate, accessible and affordable way to manage emerging health crisis In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of Gastroenterology (ACG) Annual Scientific Meeting, ...
-
Sonic Incytes Recognized as a Ready to Rocket Company For Second Year in a Row
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top ...
-
Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin
Agilent Technologies Inc. (NYSE: A) today announced that Jules Griffin has received an Agilent Thought Leader Award in recognition of his work in lipidomics. This award includes an Agilent 6560 Ion Mobility Q-TOF LC/MS system, which Dr. Griffin and his team will use to advance their lipid profiling of human tissues at the University of Cambridge. Dr. Griffin directs research into lipid profiling ...
-
Velacur Data Presented at 2021 AASLD The Liver Meeting
Greater measurement depth of novel imaging test for liver disease highlighted in presentation Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health assessment solution – will be presented during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, ...
-
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, initially targeting pediatric growth hormone deficiency, today announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (GH) secretagogue, LUM-201, in Nonalcoholic Fatty Liver Disease (NAFLD). The ...
By Lumos Pharma
-
Sonic Incytes Successfully Completes Series A Raise of US$7.3M to Accelerate VelacurTM Commercialization
Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors. The strategic equity ...
-
Fractyl Announces FDA IDE Approval to Begin Pivotal Study of Revita DMR for Insulin-Treated Patients with Type 2 Diabetes
Revita T2Di pivotal study to evaluate the ability of Revita DMR, the first non-drug, non-surgical, disease-modifying therapy, to eliminate need for insulin injections in T2D; enrollment expected to begin in late 2020 LEXINGTON, Mass., June 3, 2020 — Fractyl Laboratories Inc. (Fractyl) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) of ...
-
Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes
Revita® DMR is the first and only procedural therapy for type 2 diabetes; Revita DMR has been shown to durably improve blood sugar control without the need for escalating drug therapy and to reduce liver fat in NAFLD/NASH in clinical studies to date. LEXINGTON, Mass., August 6, 2020 – Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic ...
-
Glycotest Innovator Joins the Medical University of South Carolina as the New SmartState Endowed Chair of Proteomic Biomarkers
Glycotest, Inc. innovator Professor Anand Mehta, a leader in the development of glycoproteomic technologies for the discovery of novel cancer biomarkers, joins the Medical University of South Carolina (MUSC) and Hollings Cancer Center, Charleston, SC, as the new SmartState Endowed Chair of Proteomic Biomarkers, the company announced today (see MUSC). Mehta, whose work has resulted in 79 ...
-
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesizes multiple streams of existing evidence from ...
-
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
-
Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita DMR for Type 2 Diabetes
REVITA-T2Di study is assessing potential of outpatient Revita DMR treatment to improve glycemic control and reduce or eliminate need for daily insulin – LEXINGTON, Mass., September 1, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the activation of the tenth ...
-
Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and ...
-
Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes
Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to ...
-
HemoShear Identifies Second Target to Treat Nash for Takeda
HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited (“Takeda”) for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear’s exclusive collaboration ...
-
Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated
LEXINGTON, Mass., February 1, 2021 — Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial conducted in collaboration with Fractyl. The results demonstrate that a majority of patients ...
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you